JRJane Ravenscroft

Jane Ravenscroft

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jane Ravenscroft has a total of 212 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spironolactone for the treatment of acne vulgaris affecting female patients aged ≤ 18 years: results from a UK and Irish Survey of healthcare professionals

    by Zahra Moledina, Lisa O’HIggins, Myranda Attard, Julia Fordham, Grishma Ramesh, Fiona Sexton, Lydia Tutt, Alison Layton, Miriam Santer, Jane Ravenscroft, et al.

    A survey of UK and Irish healthcare professionals was distributed via the UK Dermatology Clinical Trials Network, British Society for Paediatric and Adolescent Dermatologists, Irish Association of Dermatologists and other regional groups. The aim was to understand how healthcare professionals prescribe spironolactone for female patients, with a particular focus on those aged ≤ 18 years, as well as concerns regarding side effects and thoughts about a future clinical trial. A total of 116 responses were received from healthcare professionals, including dermatologists, dermatology nurses, paediatricians, general practitioners and pharmacists. The results showed that there is varied clinical practice and confidence among healthcare professionals treating this population with spironolactone, with the main safety concerns being around hormonal implications, future pregnancies and lack of long-term data.

  • Translating the Eczema Bathing Study: why context and infection burden matter: reply from authors

    by Kim S Thomas, Hywel C Williams, Lucy Bradshaw, Jane Ravenscroft, Matthew J Ridd, Amanda Roberts

    Response from the authors of ‘Weekly versus daily bathing for people with eczema: results of the Eczema Bathing online randomized controlled trial’ to ‘Translating the Eczema Bathing Study: why context and infection burden matter’, by Ng et al.

  • Paediatric dermatology training experience and career intentions: a survey of UK dermatology trainees

    by Natalie King Stokes, Natalia Cartledge, Tess McPherson, Jane Ravenscroft, Lea Solman

    The NHS is currently facing a shortage of paediatric dermatologists, which is negatively impacting the care of children and young people with skin disease. We conducted a survey of UK dermatology trainees to explore the level and duration of paediatric dermatology training received during their programmes and their career intentions with regard to practising paediatric dermatology as consultants. Our results show variations in paediatric dermatology training throughout the UK and a low proportion of trainees who plan to hold paediatric dermatology clinics as consultants.


  • Open Access

    Weekly versus daily bathing for people with eczema: results of the Eczema Bathing online randomized controlled trial

    by Lucy Bradshaw, Laura M Howells, Ingrid Muller, Eleanor J Mitchell, Arabella Baker, Leila Thuma, Eleanor F Harrison, Liz Hartshorne, Yimin Jiang, Fiona Cowdell, et al.

    Background: Questions about washing are a high priority for people with eczema (also known as atopic dermatitis and atopic eczema), but they are rarely the focus of randomized controlled trials (RCTs). Objectives: To assess the impact of weekly vs. daily bathing in people with eczema in the first of a series of eczema citizen science online trials in the UK. Methods: This was a pragmatic two-arm parallel-group superiority RCT. People with self-reported eczema aged ≥ 1 years were eligible, excluding those with very mild eczema [Patient Orientated Eczema Measure (POEM) score ≤ 2]. Participants were allocated (1 : 1) using minimization, balancing on eczema severity (POEM), age and usual method of bathing to either the weekly bathing group (bath or shower once or twice weekly) or the daily bathing group (bath or shower ≥ 6 times weekly) for 4 weeks. Participants were not blinded to their allocation. The primary outcome was participant-reported eczema symptoms collected weekly over 4 weeks using POEM (range 0–28, where higher scores indicate more severe eczema). The trial was registered with ISRCTN on 22 November 2023 (https://www.isrctn.com/ISRCTN12016473). Results: In total, 438 people with eczema (108 of whom were aged < 16 years) were randomized between 29 January and 8 July 2024: 218 to daily bathing and 220 to weekly bathing. The primary analysis included 195 participants (89.4%) allocated to daily bathing and 193 (87.7%) to weekly bathing who completed at least one follow-up questionnaire. Mean (SD) POEM scores at baseline and at 1, 2, 3 and 4 weeks were 14.5 (5.7), 11.7 (5.9), 12.2 (5.9), 11.7 (6.7) and 11.6 (6.5), respectively, in the daily bathing group and 14.9 (6.3), 12.1 (6.8), 11.3 (6.7), 10.5 (7.0) and 10.6 (7.2), respectively, in the weekly bathing group. The adjusted difference in mean POEM score over 4 weeks for weekly vs. daily bathing was –0.4 (95% confidence interval –1.3 to 0.4; P = 0.30). Process evaluation data highlighted participants’ experiences of making changes to bathing routines, including barriers to following the allocated routine. No serious unintended effects or harms were reported. Conclusions: The trial found no evidence of a difference in eczema symptoms between bathing or showering weekly vs. daily. These results are helpful for people with eczema, giving them the freedom to choose what suits them best.


  • Reframing ‘dermatitis artefacta’ in children and young people as a functional skin disorder: building trust, improving communication and enhancing recovery

    by Tess McPherson, Jane C Ravenscroft, Mina Fazel, Rhiannon Nancarrow-Lei, Susannah Baron

    Dermatitis artefacta (DA) is known to have considerable burden on patients, healthcare professionals and services. We believe that the current guidance and terminology are not therapeutic. We propose a reframing of our approach, where dermatology adopts the term ‘functional skin disorders’ to cover a range of skin presentations linked to underlying psychological distress or abnormal brain/skin interaction without evidence of a primary skin disorder. This includes specific focus on DA. We offer input and reflections to help manage these presentations in a way that is consistent, focuses on the needs of our patients and offers a better prospect for sustainable recovery.

  • Open Access

    Exposure–response of ciclosporin and methotrexate in children and young people with severe atopic dermatitis: a secondary analysis of the TREatment of severe Atopic dermatitis Trial (TREAT)

    by Mandy Wan, Ashley P Jones, Daniel Maskrey, Monica Arenas-Hernandez, Anna Rosala-Hallas, Paula E Beattie, Susannah Baron, Fiona Browne, Sara J Brown, Joanna E Gach, et al.

    This is a secondary analysis of a multicentre randomized controlled trial of ciclosporin and methotrexate in children and young people (CYP) with severe atopic dermatitis (AD). Longitudinal trough ciclosporin and erythrocyte methotrexate polyglutamate (MTX-PG) concentrations were measured to evaluate their associations with treatment response and adverse events. Both ciclosporin (4 mg kg–1 daily) and methotrexate (0.4 mg kg–1 weekly) led to a significant reduction in disease severity scores over the 36-week treatment period. Higher trough ciclosporin concentrations were associated with lower disease severity scores and may serve as a useful tool for therapeutic drug monitoring of ciclosporin in CYP with AD. However, in contrast to a previously published study, steady-state erythrocyte-MTX-PG concentrations showed no significant association with treatment response. Drug concentrations were comparable between patients with and without drug-related adverse events.

  • Open Access

    The Eczema Bathing Study: Weekly versus daily bathing for people with eczema? Protocol of an online, randomised controlled trial

    by Wei Chern Gavin Fong, Laura Howells, Ingrid Muller, Eleanor J Mitchell, Arabella Baker, Leila Thuma, Eleanor Harrison, Lucy Bradshaw, Yimin Jiang, Fiona Cowdel, et al.

    Background A priority setting partnership for eczema (syn atopic eczema, atopic dermatitis) has identified that bathing frequency is a key area of patient interest. However, there are nolarge, high-quality randomised controlled trials (RCTs) investigating this. The Rapid Eczema Trials project is a novel programme of research that aims to deliver multiple online RCTs, using a citizen science approach. This project involves working with members of the public to co-design and conduct studies that answer questions of importance to them. The first trial to be conducted through this project is assessing the impact of bathing frequency on eczema. Methods This is an online, two-arm, parallel-group superiority RCT with internal pilot phase. People aged ≥1 year with eczemaliving in the United Kingdom are eligible. Exclusion criteria are: people with other types of eczema such as venous eczema, hand eczema and contact eczema; recently started a new eczema treatment; taking part in another eczema trial; Patient Oriented Eczema Measure (POEM) ≤2; planning to swim more than twice a week; unable/unwilling to change bathing practices. Participants are allocated 1:1 to either the weekly bathing group (bathe 1 or 2 times a week) or the daily bathing group (bathe 6 or more times a week) for 4 weeks. The primary outcome is POEM, assessed weekly over 4 weeks. Secondary outcomes include skin specific quality of life, eczema control, itch severity, use of usual eczema treatments, proportion who achieve an improvement in POEM of ≥3 points, global change in eczema and safety outcomes. A sample of participants will also be invited to a semi-structured interview to discuss their experience. The primary comparative analysis will be according to randomised allocation regardless of actual frequency of bathing. The trial will be reported in accordance with CONSORT guidelines. The study has received ethical approval by the London - Surrey Research Ethics Committee (2 Redman Place, London, E20 1JQ, United Kingdom) on 11/10/2023 ( approval number: 23/PR/0899). Trial registration ISRCTN12016473, 22/11/2023, https://doi.org/10.1186/ISRCTN12016473


  • Open Access

    The Eczema Bathing Study: Weekly versus daily bathing for people with eczema? Protocol of an online, randomised controlled trial

    by Wei Chern Gavin Fong, Laura Howells, Ingrid Muller, Eleanor J Mitchell, Arabella Baker, Leila Thuma, Eleanor Harrison, Lucy Bradshaw, Yimin Jiang, Fiona Cowdel, et al.

    Background A priority setting partnership for eczema (syn atopic eczema, atopic dermatitis) has identified that bathing frequency is a key area of patient interest. However, there are nolarge, high-quality randomised controlled trials (RCTs) investigating this. The Rapid Eczema Trials project is a novel programme of research that aims to deliver multiple online RCTs, using a citizen science approach. This project involves working with members of the public to co-design and conduct studies that answer questions of importance to them. The first trial to be conducted through this project is assessing the impact of bathing frequency on eczema. Methods This is an online, two-arm, parallel-group superiority RCT with internal pilot phase. People aged ≥1 year with eczemaliving in the United Kingdom are eligible. Exclusion criteria are: people with other types of eczema such as venous eczema, hand eczema and contact eczema; recently started a new eczema treatment; taking part in another eczema trial; Patient Oriented Eczema Measure (POEM) ≤2; planning to swim more than twice a week; unable/unwilling to change bathing practices. Participants are allocated 1:1 to either the weekly bathing group (bathe 1 or 2 times a week) or the daily bathing group (bathe 6 or more times a week) for 4 weeks. The primary outcome is POEM, assessed weekly over 4 weeks. Secondary outcomes include skin specific quality of life, eczema control, itch severity, use of usual eczema treatments, proportion who achieve an improvement in POEM of ≥3 points, global change in eczema and safety outcomes. A sample of participants will also be invited to a semi-structured interview to discuss their experience. The primary comparative analysis will be according to randomised allocation regardless of actual frequency of bathing. The trial will be reported in accordance with CONSORT guidelines. The study has received ethical approval by the London - Surrey Research Ethics Committee (2 Redman Place, London, E20 1JQ, United Kingdom) on 11/10/2023 ( approval number: 23/PR/0899). Trial registration ISRCTN12016473, 22/11/2023, https://doi.org/10.1186/ISRCTN12016473


  • Open Access

    The effects of ciclosporin and methotrexate on kidney function in the treatment of severe atopic dermatitis in children: results from the TREAT trial

    by Gordon Bruce, Anna Rosala-Hallas, Ashley P Jones, Charles Turner, Neil Dalton, Eva Hilger, Susannah Baron, Paula Beattie, Fiona Browne, Sara J Brown, et al.

    Ciclosporin (CyA) and methotrexate (MTX) are frequently prescribed drugs for the treatment of atopic dermatitis in children and young people. Both can affect renal function and frequent blood monitoring is standard to monitor safety. We show that both CyA and MTX are not associated with decreased renal function and are safe and effective as a treatment for atopic dermatitis in children and young people.


  • Open Access

    Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial

    by Carsten Flohr, Anna Rosala-Hallas, Ashley P Jones, Paula Beattie, Susannah Baron, Fiona Browne, Sara J Brown, Joanna E Gach, Danielle Greenblatt, Ross Hearn, et al.

    Background: Conventional systemic drugs are used to treat children and young people (CYP) with severe atopic dermatitis (AD) worldwide, but no robust randomized controlled trial (RCT) evidence exists regarding their efficacy and safety in this population. While novel therapies have expanded therapeutic options, their high cost means traditional agents remain important, especially in lower-resource settings. Objectives: To compare the safety and efficacy of ciclosporin (CyA) with methotrexate (MTX) in CYP with severe AD in the TREatment of severe Atopic Eczema Trial (TREAT) trial. Methods: We conducted a parallel group assessor-blinded RCT in 13 UK and Irish centres. Eligible participants aged 2–16 years and unresponsive to potent topical treatment were randomized to either oral CyA (4 mg kg–1 daily) or MTX (0.4 mg kg–1 weekly) for 36 weeks and followed-up for 24 weeks. Co-primary outcomes were change from baseline to 12 weeks in Objective Severity Scoring of Atopic Dermatitis (o-SCORAD) and time to first significant flare (relapse) after treatment cessation. Secondary outcomes included change in quality of life (QoL) from baseline to 60 weeks; number of participant-reported flares following treatment cessation; proportion of participants achieving ≥ 50% improvement in Eczema Area and Severity Index (EASI 50) and ≥ 75% improvement in EASI (EASI 75); and stratification of outcomes by filaggrin status. Results: In total, 103 participants were randomized (May 2016–February 2019): 52 to CyA and 51 to MTX. CyA showed greater improvement in disease severity by 12 weeks [mean difference in o-SCORAD –5.69, 97.5% confidence interval (CI) –10.81 to –0.57 (P = 0.01)]. More participants achieved ≥ 50% improvement in o-SCORAD (o-SCORAD 50) at 12 weeks in the CyA arm vs. the MTX arm [odds ratio (OR) 2.60, 95% CI 1.23–5.49; P = 0.01]. By 60 weeks MTX was superior (OR 0.33, 95% CI 0.13–0.85; P = 0.02), a trend also seen for ≥ 75% improvement in o-SCORAD (o-SCORAD 75), EASI 50 and EASI 75. Participant-reported flares post-treatment were higher in the CyA arm (OR 3.22, 95% CI 0.42–6.01; P = 0.02). QoL improved with both treatments and was sustained after treatment cessation. Filaggrin status did not affect outcomes. The frequency of adverse events (AEs) was comparable between both treatments. Five (10%) participants on CyA and seven (14%) on MTX experienced a serious AE. Conclusions: Both CyA and MTX proved effective in CYP with severe AD over 36 weeks. Participants who received CyA showed a more rapid response to treatment, while MTX induced more sustained disease control after discontinuation.